(R)-tert-Butyl 3-((6-aminopyrazin-2-yl)oxy)piperidine-1-carboxylate

Catalog No. :
ACJOCD952
CAS No. :
1417789-26-4
Molecular Formula :
C14H22N4O3
Molecular Weight :
294.36

IUPAC Name:tert-butyl (R)-3-((6-aminopyrazin-2-yl)oxy)piperidine-1-carboxylate

(R)-tert-Butyl 3-((6-aminopyrazin-2-yl)oxy)piperidine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$202.00Login to see priceInquiryInquiry
250mg95%$341.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-tert-Butyl 3-((6-aminopyrazin-2-yl)oxy)piperidine-1-carboxylate
IUPAC Nametert-butyl (R)-3-((6-aminopyrazin-2-yl)oxy)piperidine-1-carboxylate
Molecular FormulaC14H22N4O3
Molecular Weight294.36
SMILESO=C(N1C[C@H](OC2=NC(N)=CN=C2)CCC1)OC(C)(C)C
InChI KeyGIHFUWYGGUNZCV-SNVBAGLBSA-N
Synonym(R)-3-(6-AMino-pyrazin-2-yloxy)-piperidine-1-carboxylic acid tert-butyl ester;(R)-tert-Butyl 3-((6-aMinopyrazin-2-yl)oxy)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 3-[(6-amino-2-pyrazinyl)oxy]-, 1,1-dimethylethyl ester, (3R)-
CAS No.1417789-26-4

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACJOCD952 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACRDMW724 route compound structure diagram
    ACRDMW724143900-43-0 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACJOCD952 route product structure diagram
    ACJOCD9521417789-26-4
Inquiry

2. ACJOCD952 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACJOCD952 route product structure diagram
    ACJOCD9521417789-26-4
Inquiry

Comments (0)